Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor

Journal of Inflammation Research

Volumn 7, Issue 1, 2014, Pages 121-131

  Manetta, Joseph ^a   Bina, Holly ^a   Ryan, Paul ^a   Fox, Niles ^a   Witcher, Derrick R ^a   Kikly, Kristine ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Autoimmunity; B cell malignancies; B cell survival factor; BAFF

Indexed keywords

B CELL ACTIVATING FACTOR; FREUND ADJUVANT; IMMUNOLOGIC AGENT; PROTEIN P52; RECOMBINANT B CELL ACTIVATING FACTOR; TABALUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURFACE PLASMON RESONANCE;

EID: 84923330305     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S67751     Document Type: Article

References (38)

1. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002; 2(7): 465-475.
2. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999; 189(11): 1747-1756.
3. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001; 97(1): 198-204.
4. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009; 9(7): 491-502.
5. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004; 173(2): 807-817.
6. Goenka R, Matthews AH, Zhang B, et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014; 211(1): 45-56.
7. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin6deprivation and dexamethasone. Blood. 2004; 103(8): 3148-3157.
8. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology. 2006; 118(3): 281-292.
9. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001; 44(6): 1313-1319.
10. Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007; 13(19): 5903-5909.
11. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20(6): 785-798.
12. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004; 20(4): 441-453.
13. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003; 48(12): 3475-3486.
14. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008; 58(8): 2453-2459.
15. Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol. 2008; 181(3): 2211-2219.
16. Tan SM, Xu D, Roschke V, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003; 48(4): 982-992.
17. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase3trial. Lancet. 2011; 377(9767): 721-731.
18. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63(12): 3918-3930.
19. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003; 48(11): 3253-3265.
20. Zola H. Monoclonal Antibodies: A Manual of Techniques. Boca Raton (FL): CRC Press; 1987.
21. Tosato G, Seamon KB, Goldman ND, et al. Monocyte-derived human B-cell growth factor identified as interferon-beta2 (BSF-2, IL-6). Science. 1988; 239(4839): 502-504.
22. Fox N, Solter D. Expression and regulation of the pituitary-and placenta-specific human glycoprotein hormone alpha-subunit gene is restricted to the pituitary in transgenic mice. Mol Cell Biol. 1988; 8(12): 5470-5476.
23. Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009; 27(8): 767-771.
24. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999; 285(5425): 260-263.
25. Claudio E, Brown K, Park S, Wang H, SiebenlistU. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 2002; 3(10): 958-965.
26. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the80 kDa tumor necrosis factor receptor. Cell. 1995; 83(5): 793-802.
27. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010; 49(7): 1215-1228.
28. Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood. 2008; 111(3): 1004-1012.
29. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med. 2003; 198(6): 937-945.
30. Bossen C, Tardivel A, Willen L, et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol. 2011; 41(3): 787-797.
31. Rochas C, Hillion S, Saraux A, et al. Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes. Arthritis Rheum. 2009; 60(5): 1261-1271.
32. Chu VT, Enghard P, Riemekasten G, Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol. 2007; 179(9): 5947-5957.
33. Abu-Rish EY, Amrani Y, Browning MJ. Toll-like receptor9activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF. Rheumatology (Oxford). 2013; 52(7): 1190-1201.
34. Kikly K, Manetta J, Smith H, Wierda D, Witcher D. Characterization of LY2127399, A neutralizing antibody for BAFF. Arthritis Rheum. 2009; 60: S10.
35. Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2013; 65(4): 880-889.
36. Badr G, Borhis G, Lefevre EA, et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood. 2008; 111(5): 2744-2754.
37. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009; 61(9): 1168-1178.
38. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebocontrolld trial. Arthritis Rheum. 2011; 63(7): 1782-1792.